Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748355 · ClinicalTrials.gov registry record · NA
Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT03748355: Completed NA study, sponsored by Mayo Clinic.
NCT03748355 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03748355, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
The Researchers are trying to learn more about how individuals break down and process medications based on their genes. The Researchers want to find out whether subjects will have fewer side effects if they take different medications based on their pharmacogenomics profile.
Interventions
- GENETIC Pharmacogentic Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-10-14 |
| Est. Completion | 2020-01-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03748355
The ClinicalTrials.gov registry entry for NCT03748355 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pharmacogentic Analysis is the first listed.
NCT03748355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03748355 about?
NCT03748355 is a clinical study titled "Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects". The Researchers are trying to learn more about how individuals break down and process medications based on their genes. The Researchers want to find out whether subjects will have fewer side effects if they take different medications based on their pharmacogenomics profile.
What is the current status of trial NCT03748355?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2018-10-14. Estimated completion is 2020-01-02.
What interventions are being tested in trial NCT03748355?
The interventions under investigation include: Pharmacogentic Analysis (GENETIC).
Who is sponsoring clinical trial NCT03748355?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.